Dr Rosenstein breaks down the Ozempic face term and says weight loss can help some patients, though not everyone needs the same approach.
Recap by typeshit. Post by @dr_rosenstein on Instagram.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
The appeal board went against its preliminary opinion. JUVE Patent says generic semaglutide could reach Europe as early as 2031 instead of 2037.
Lilly closed at $1,169.60, and one widely followed narrative pegs fair value near $1,477, citing retatrutide's Phase 3 results against pricing pressure.
Loading…